{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T20:00:25Z","timestamp":1772654425980,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"French Ministry of Research"},{"DOI":"10.13039\/501100004099","name":"National League against Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Institute of Research in Public Health - National Institute of Health and Medical Research"},{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-01792-w","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T09:23:50Z","timestamp":1747041830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the coblance cohort"],"prefix":"10.1186","volume":"25","author":[{"given":"Ald\u00e9ric","family":"Fraslin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Colrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Bonastre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Groussard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siguroli","family":"Teitsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Prudent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Branchoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Radvanyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Lebret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"1792_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.005.","journal-title":"Eur J Cancer"},{"key":"1792_CR2","doi-asserted-by":"publisher","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder Cancer. Med Sci (Basel). 2020;8(1). https:\/\/doi.org\/10.3390\/medsci8010015.","DOI":"10.3390\/medsci8010015"},{"issue":"3","key":"1792_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"1792_CR4","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: A review. JAMA. 2020;324(19):1980\u201391. https:\/\/doi.org\/10.1001\/jama.2020.17598.","journal-title":"JAMA"},{"key":"1792_CR5","volume-title":"TNM classification of malignant tumours, eighth edition","author":"JG Brierley","year":"2017","unstructured":"Brierley JG, Wittekind MK. C.: TNM classification of malignant tumours, eighth edition. Chichester, West Sussex, UK; Hoboken, NJ: John Wiley & Sons, Inc; 2017."},{"issue":"1","key":"1792_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"JA Witjes","year":"2024","unstructured":"Witjes JA, Bruins HM, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol. 2024;85(1):17\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.016.","journal-title":"Eur Urol"},{"issue":"1","key":"1792_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comperat EM, Cowan NC, Gakis G, et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055.","journal-title":"Eur Urol"},{"issue":"15","key":"1792_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.purol.2022.07.145","volume":"32","author":"Y Neuzillet","year":"2022","unstructured":"Neuzillet Y, Audenet F, Loriot Y, Allory Y, Masson-Lecomte A, Leon P, et al. French AFU Cancer committee Guidelines - Update 2022\u20132024: Muscle-Invasive bladder Cancer (MIBC). Prog Urol. 2022;32(15):1141\u201363. https:\/\/doi.org\/10.1016\/j.purol.2022.07.145.","journal-title":"Prog Urol"},{"issue":"1","key":"1792_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12885-016-2877-x","volume":"16","author":"S Benhamou","year":"2016","unstructured":"Benhamou S, Bonastre J, Groussard K, Radvanyi F, Allory Y, Lebret T. A prospective multicenter study on bladder cancer: the coblance cohort. BMC Cancer. 2016;16(1):837. https:\/\/doi.org\/10.1186\/s12885-016-2877-x.","journal-title":"BMC Cancer"},{"issue":"12","key":"1792_CR10","doi-asserted-by":"publisher","first-page":"e075942","DOI":"10.1136\/bmjopen-2023-075942","volume":"13","author":"T Lebret","year":"2023","unstructured":"Lebret T, Bonastre J, Fraslin A, Neuzillet Y, Droupy S, Rebillard X, et al. Cohort profile: coblance: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life. BMJ Open. 2023;13(12):e075942. https:\/\/doi.org\/10.1136\/bmjopen-2023-075942.","journal-title":"BMJ Open"},{"issue":"1","key":"1792_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42\u201354. https:\/\/doi.org\/10.1016\/j.eururo.2013.08.033.","journal-title":"Eur Urol"},{"issue":"1","key":"1792_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.eururo.2012.08.010","volume":"63","author":"CN Sternberg","year":"2013","unstructured":"Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, et al. ICUD-EAU international consultation on bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013;63(1):58\u201366. https:\/\/doi.org\/10.1016\/j.eururo.2012.08.010.","journal-title":"Eur Urol"},{"issue":"1","key":"1792_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","volume":"16","author":"CN Sternberg","year":"2015","unstructured":"Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N + M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(1):76\u201386. https:\/\/doi.org\/10.1016\/S1470-2045(14)71160-X.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1792_CR14","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/cncr.31952","volume":"125","author":"S Berg","year":"2019","unstructured":"Berg S, D\u2019Andrea D, Vetterlein MW, Cole AP, Fletcher SA, Krimphove MJ, et al. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: does histologic subtype matter? Cancer. 2019;125(9):1449\u201358. https:\/\/doi.org\/10.1002\/cncr.31952.","journal-title":"Cancer"},{"issue":"8","key":"1792_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JCO.2015.64.1076","volume":"34","author":"MD Galsky","year":"2016","unstructured":"Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder Cancer. J Clin Oncol. 2016;34(8):825\u201332. https:\/\/doi.org\/10.1200\/JCO.2015.64.1076.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1792_CR16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00345-023-04335-w","volume":"41","author":"M Roupret","year":"2023","unstructured":"Roupret M, Brouquet A, Colrat F, Diez-Andreu P, Prudent A, Chartier M, et al. Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study. World J Urol. 2023;41(4):1069\u201375. https:\/\/doi.org\/10.1007\/s00345-023-04335-w.","journal-title":"World J Urol"},{"issue":"1","key":"1792_CR17","doi-asserted-by":"publisher","first-page":"7543","DOI":"10.1038\/s41598-018-26002-6","volume":"8","author":"P Ge","year":"2018","unstructured":"Ge P, Wang L, Lu M, Mao L, Li W, Wen R, et al. Oncological outcome of primary and secondary Muscle-Invasive bladder cancer: A systematic review and Meta-analysis. Sci Rep. 2018;8(1):7543. https:\/\/doi.org\/10.1038\/s41598-018-26002-6.","journal-title":"Sci Rep"},{"issue":"22","key":"1792_CR18","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in Muscle-Invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2034442.","journal-title":"N Engl J Med"},{"issue":"13","key":"1792_CR19","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01792-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01792-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01792-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T09:23:52Z","timestamp":1747041832000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01792-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1792"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01792-w","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and applicable regulatory requirements. The COBLAnCE study was approved by the relevant French ethics committee (Comit\u00e9 de Protection des Personnes Ile de France VII; approval n\u00b0 CO-12-001), the French data protection authority (Commission Nationale de l\u2019Informatique et des Libert\u00e9s; approval n\u00b0 DR-2012-441) and the French biological tissue collection authority (approval n\u00b0 DR-2012-1486). Each patient enrolled provided written informed consent. The current study did not require additional approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Julia Bonastre reports consulting fees for scientific advisory board from Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Janssen and Roche. Yves Allory reports fees to Institut Curie from Bristol Myers Squibb and Merck Sharp & Dome. Thierry Lebret reports personal fees from Bristol Myers Squibb and Ferring. Simone Benhamou reports personal fees from AstraZeneca. Florian Colrat, Siguroli Teitsson, Alexis Prudent and S\u00e9bastien Branchoux are employees of Bristol Myers Squibb. Ald\u00e9ric Fraslin, Maryam Karimi, Karine Groussard and Fran\u00e7ois Radvanyi declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}